Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)

AIMS: Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion. METHODS AND RESULTS: Patients with AF and more than one risk factor for stro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Connolly, Stuart J., Eikelboom, John, Dorian, Paul, Hohnloser, Stefan H., Gretler, Daniel D., Sinha, Uma, Ezekowitz, Michael D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3659305/
https://ncbi.nlm.nih.gov/pubmed/23487517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/eht039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados